Vectura in global development programme

Vectura has signed a development and licence agreement with Mundipharma International and a US independent associated company as the global development and commercialisation partner for the VR2076 (previously SKP-2076) pressurised Metered Dose Inhaler (pMDI) ICS/LABA/LAMA triple programme.

In December 2015, the companies entered into a feasibility and option agreement and following successful completion of the feasibility work, which Vectura was responsible for, Mundipharma and the US associated independent company have now confirmed they will exercise the option to develop and commercialise VR2076 initially in asthma.

The exercise of this option triggers a payment to Vectura of €1.5 million. The Group’s R&D investment guidance for 2016 and 2017, provided recently in its interim results statement in November, remains unchanged.

Further total potential milestone payments up to €46.5 million are receivable linked to development, regulatory and launch progress of the programme as well as royalties on any future net sales of the product.

The royalty rate on this novel product development programme, where Vectura has been responsible for the formulation development, is initially around a mid-single digit percentage but could increase depending on sales.

This agreement also includes the potential for further development of the triple combination treatment for chronic obstructive pulmonary disease (“COPD”).

If Mundipharma decides to develop the programme in COPD, Vectura is eligible for further potential milestones linked to the regulatory progress of the programme up to €20.0 million as well as royalties on any future net sales of the product. The royalty rate on net sales for the COPD indication product would be the same as the asthma indication product. In addition, Vectura will also receive one-off undisclosed sales milestones should net sales of both the asthma and COPD products achieve certain predetermined levels.

The first regulatory filings of VR2076 are planned in the EU for late 2022/early 2023.

Story provided by StockMarketWire.com

66% off newsstand price

12 issues (and much more) for just £12

That’s right. We’ll give you 12 issues of MoneyWeek magazine, complete access to our exclusive web articles, our latest wealth building reports and videos as well as our subscriber-only email… for just £12.

That’s just £1 per week for Britain’s best-selling financial magazine.

Click here to take advantage of our offer

Britain is leaving the European Union. Donald Trump is reducing America’s role in global markets. Both will have profound consequences for you as an investor.

MoneyWeek analyses the critical issues facing British investors on a weekly basis. And, unlike other publications, we provide you with the solutions to help you turn a situation to your financial advantage.

Take up our offer today, and we’ll send you three of our most important investment reports:

All three of these reports are yours when you take up our 12 issues for £12 offer today.

MoneyWeek has been advising private British investors on what to do with their money since 2000. Our calls over that period have enabled our readers to both make and save a great deal of money – hence our position as the UK’s most-trusted investment publication.

Click here to subscribe for just £12